BTKi in R/R CLL and MCL

CME

A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 16, 2022

Expiration: December 15, 2023

Othman Al-Sawaf
Othman Al-Sawaf, MD
Matthew S. Davids
Matthew S. Davids, MD, MMSc
Toby A Eyre
Toby A Eyre, MBChB, MD
Christopher R. Flowers
Christopher R. Flowers, MD, MS
Brad S. Kahl
Brad S. Kahl, MD
Kami Maddocks
Kami Maddocks, MD
Anthony Mato
Anthony Mato, MD, MSCE
Lydia Scarfò
Lydia Scarfò, MD
Julie M. Vose
Julie M. Vose, MD

Activity

Progress
1
Course Completed
References

  1. Wang M, Jurczak W, Jerkeman M, et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract LBA7502.
  2. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482-2494.
  3. Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Presented at: 2020 American Society of Hematology annual meeting; December 5-7, 2020. Abstract 123.
  4. Ghia P, Allan JN, Siddiqi T, et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. Presented at: 2021 American Society of Clinical Oncology annual meeting; June 4-8, 2021. Abstract 7501.
  5. Wierda WG, Barr PM, Siddiqi T, et al. Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract 7519.
  6. Kater A, Owen C, Moreno C, et al. Fixed duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: primary analysis of the phase 3 GLOW study. Presented at: 2021 European Hematology Association annual meeting; June 9-17, 2021. Abstract LB1902.
  7. Lee HJ, Choi MY, Siddiqi T, et al. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract 7520.
  8. Mato AR, Pagel JM, Coombs CC, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract S147.
  9. Lewis K, Wang ML, Shah NN, et al. Pirtobrutinib, a highly selective, non-covalent (REVERSIBLE) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022.
  10. Eichhorst B, Niemann C, Kater A, et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract LB2365.
  11. Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. Presented at: 2021 American Society of Hematology annual meeting; December 10-14 2021. Abstract 71.
  12. Hillmen P, Pitchford A, Bloor A, et al. The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract S145.
  13. Davids M, Sharman J, Ghia P, et al. Long-term efficacy of acalabrutinib-based regimens in patients with chronic lymphocytic leukemia and higher-risk genomic features: pooled analysis of clinical trial data. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract P667.
  14. Kahl BS, Giannopoulos K, Jurczak W, et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022.
  15. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031-1043.
  16. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease outcomes after fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of CLL in older adult or unfit patients: the GLOW study. Presented at: 2022 Society of Hematologic Oncology annual meeting; September 28 - October 1, 2022. Abstract CLL-106.
  17. Brown JR, Hillmen P, Eichhorst B, et al. CLL-115 first interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Clin Lymphoma Myeloma Leuk. 2022;22(suppl 1):S266.
  18. Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516-5525.
  19. Munir T, Pitchford A, Bloor A, et al. Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: analysis from the phase III NCRI FLAIR trial. Presented at: 2021 American Society of Hematology; December 10-14, 2021. Abstract 2636.
  20. Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2022;[Epub ahead of print].
  21. Coombs CC, Pagel JM, Shah NN, et al. CLL-120 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk. 2022;22:S268.
  22. Cohen JB, Shah NN, Alencar AJ, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Presented at: 2022 Society of Hematologic Oncology annual meeting; September 28 - October 1, 2022. Abstract MCL-133.
  23. Wanchoo R, Ramirez CB, Barrientos J, et al. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11:670-680.
  24. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 2021 European Hematology Association Congress; June 9-17, 2021. Abstract LB1900.
  25. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7500.
  26. Rivera D, Ferrajoli A. Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr Oncol Rep. 2022;24:1003-1014.
  27. Shanafelt TD, Xang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112-120.